JOHN HOPE FRANKLIN CENTER

NeOnc Technologies has appointed two distinguished Duke University neuro-oncologists, Dr. David M. Ashley and Dr. Henry S. Friedman, to its scientific advisory board to guide development of CNS cancer therapies.

Duke University biomedical engineers have created TuNa-AI, an artificial intelligence platform that combines automated wet lab techniques to design optimized nanoparticles for drug delivery applications.

A modified CD40 agonist antibody called 2141-V11 demonstrated remarkable efficacy in a phase 1 clinical trial, with six of 12 patients experiencing significant tumor reduction and two achieving complete remission.

NeOnc Technologies received FDA authorization to proceed with Phase IIa/IIb clinical trial of NEO212, a first-in-class oral chemical conjugated chemotherapy candidate for brain cancer.

Baylor College of Medicine and Duke University are conducting a clinical trial combining chemotherapy and immunotherapy before and after surgery for resectable mesothelioma patients, enrolling 52 participants.

Agenus announced the launch of the BATTMAN Phase 3 trial evaluating botensilimab (BOT) and balstilimab (BAL) combination therapy in metastatic microsatellite stable colorectal cancer patients who have exhausted treatment options.

UroMems received investigational device exemption approval from the FDA and French ANSM to begin the SOPHIA2 pivotal trial of its UroActive smart implant for treating male stress urinary incontinence.

Fifty1 AI Labs successfully completed the REVIVE Adaptive Platform Trial, the largest and most rigorous Long COVID study to date, enrolling over 600 participants across multiple global sites.

Genflow Biosciences has formalized partnerships with Belgian research center CER Groupe and Duke University spin-out Heureka Labs to accelerate its gene therapy programs targeting age-related diseases.

Invivyd's CANOPY Phase 3 trial demonstrated that PEMGARDA (pemivibart) achieved an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months (nominal p <0.0001).